Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

The resistance story: how gonorrhea defeated nearly every antibiotic

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Gonorrhea has beaten every class of antibiotic ever used against it, usually within a decade or two. For several years, ceftriaxone by injection was the only recommended treatment left anywhere.

In December 2025 that changed. Here is how the field got to this point and where it stands now.

Related pages: Gonorrhea

The bottom line

What we know
  • N. gonorrhoeae takes up loose DNA from its environment, including resistance genes from harmless relatives in the throat.
  • Sulfonamides, penicillin, tetracyclines, ciprofloxacin and azithromycin have all been lost in turn.
  • The current first-line treatment is a single 500 mg injection of ceftriaxone.
  • In December 2025 the FDA approved two new oral antibiotics, gepotidacin and zoliflodacin.
What is still open
  • How long the new drugs will last before resistance appears.
  • Whether they will work well enough for throat infections, where they aren't approved.

The story, step by step

  1. 1. Why it adapts ()
  2. 2. 1930s to 1980s ()
  3. 3. 1990s to 2010s (US surveillance programs and others)
  4. 4. The last line (National surveillance programs)
  5. 5. December 2025 (GSK (gepotidacin) and Entasis (zoliflodacin))
  6. 6. What it means for you ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 6

A bacterium that picks up DNA off the floor

Lab or animal study

What happens

N. gonorrhoeae is naturally competent, meaning it takes up loose DNA from its surroundings and stitches useful pieces into its own genome.

What the research shows

  • Harmless Neisseria species live in most people's throats, and they share DNA with the gonococcus.
  • Those relatives are exposed to every antibiotic a person ever takes, for any reason, and accumulate resistance genes.
  • A throat gonorrhea infection sits right in that pool, which is why the throat is called a resistance reservoir.
  • On top of this, ordinary mutations in the bacterium's own genes contribute resistance.

Why it matters

This isn't bad luck. It's a bacterium built to acquire other organisms' solutions, living in the one place where those solutions accumulate.

What's still uncertain

  • How much resistance comes from gene transfer versus mutation differs by drug class.

Read more

Next: 1930s to 1980s

Part 2 of 6

Sulfa drugs, then penicillin, then tetracycline

Review of many studies

What happens

Each new class was introduced with confidence and lost within years to decades.

What the research shows

  • Sulfonamides arrived in the 1930s and resistance emerged within about a decade.
  • Penicillin replaced them in the 1940s. Doses had to be raised repeatedly as sensitivity fell.
  • In the 1970s and 1980s, strains appeared carrying plasmids with beta-lactamase, an enzyme that chemically destroys penicillin.
  • Tetracyclines went the same way.

Why it matters

The pattern was established early: effective drug, rising doses, then abandonment.

What's still uncertain

  • Exact timelines differ between countries, and resistance often appeared in some regions long before others.

Read more

Next: 1990s to 2010s

Part 3 of 6

Ciprofloxacin, then azithromycin

US surveillance programs and othersLarge observational study

What happens

Fluoroquinolones such as ciprofloxacin became standard in the 1990s because they were oral, cheap and effective.

What the research shows

  • Mutations in the bacterium's DNA-gyrase enzyme made them fail, and in 2007 US guidance stopped recommending them.
  • That left cephalosporins as the only recommended class.
  • To protect them, guidance moved to dual therapy: a ceftriaxone injection plus oral azithromycin.
  • Azithromycin resistance then rose, and in December 2020 US guidance dropped it, returning to ceftriaxone alone, at a higher 500 mg dose.

Why it matters

Dual therapy was a deliberate attempt to slow resistance. It bought about a decade.

What's still uncertain

  • Whether dropping azithromycin was the right call is still discussed among specialists.

Read more

Next: The last line

Part 4 of 6

Ceftriaxone alone, and the strains that beat it

National surveillance programsLarge observational study

What happens

For several years a single injection of ceftriaxone was the only recommended treatment in most countries.

What the research shows

  • The dose is 500 mg into a muscle for most people, or 1 g for people weighing 150 kg or more.
  • It covers urethral, cervical, rectal and throat infections.
  • Strains with reduced susceptibility to ceftriaxone, and some fully resistant, have been found in several countries and have reached the United States.
  • Canada's surveillance identified 13 ceftriaxone-resistant cases between 2017 and 2024, which gives a sense of how rare but real this is.
  • Throat infections are hardest to clear, which is why a follow-up test is recommended for them.

Why it matters

Resistant cases are still rare, and most people are cured by the standard shot. But the margin had become uncomfortably thin.

What's still uncertain

  • Surveillance is patchy worldwide, so true rates are unknown in many countries.

Read more

Next: December 2025

Part 5 of 6

Two new oral antibiotics, the first new class in decades

GSK (gepotidacin) and Entasis (zoliflodacin)United StatesRandomized trial

What happens

Both drugs block bacterial DNA replication at binding sites different from existing antibiotics, so existing resistance doesn't apply.

What the research shows

  • Gepotidacin (Blujepa) was approved on 11 December 2025 for uncomplicated urogenital gonorrhea in people aged 12 and over. In the EAGLE-1 trial, two oral 3,000 mg doses cured 92.6% of urogenital infections against 91.2% for the injection plus azithromycin.
  • Zoliflodacin (Nuzolvence) was approved the next day. In its phase 3 trial of 930 people, a single oral dose cured 90.9% against 96.2% for the standard combination.
  • Both are approved only for uncomplicated urogenital infection, not rectal or throat infection.
  • Both are intended for people with limited treatment options, not as a general replacement for the injection.

Why it matters

After decades with the pipeline nearly empty, there are now oral options that work against resistant strains. The injection remains the standard first-line treatment.

What's still uncertain

  • Safety data in wider use is still limited, which is why health departments are restricting them.
  • Not being approved for throat infection matters, because that is where resistance develops.
  • Resistance to these will eventually appear. The history on this page is the reason to assume so.

Read more

Next: What it means for you

Part 6 of 6

What this changes for someone being treated

Review of many studies

What happens

Translating all of this into practice.

What the research shows

  • The injection is still what almost everyone will be given, and it still works for almost everyone.
  • Finish the whole treatment, and never use leftover or shared antibiotics. Partial treatment is exactly how resistance is bred.
  • Come back if symptoms don't settle within a few days. That can be a sign of a resistant strain and is worth culturing.
  • A throat infection needs a follow-up test about 1 to 2 weeks after treatment.
  • Getting partners treated prevents reinfection and limits how much the bacterium circulates and swaps genes.

Why it matters

The individual advice and the global resistance problem are the same advice. Taking treatment properly is a public act as much as a personal one.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.